The drug was approved with a broad label. OrbiMed is holding 2.7 million shares. They didn't get stupid overnight. Don't complain, take advantage of the price. There have been large bids starting in the low 9s. The company starts out with about $15 million in revenue already, and in two months EXPAREL revenue will start coming in. Management is smart, experienced, and has been working ever since the IPO to get ready for the launch. The DepoFoam platform can produce many more drugs.